Genesis Molecular AI, Inc (formerly Genesis Therapeutics) originated from Stanford University’s Vijay Pande lab, where foundational research in graph machine learning laid the groundwork for the company’s innovative approach to designing the next generation of medicines for patients with severe unmet medical needs.
Genesis is pioneering foundation models for molecular AI to unlock a new era of drug design and development. The company’s generative and predictive AI platform, GEMS (Genesis Exploration of Molecular Space), integrates AI and physics into industry-leading models to generate and optimize drug molecules, including the breakthrough generative diffusion model Pearl for structure prediction.
Genesis has raised over $300 million from leading AI, tech and life science-focused investors, signed multiple AI-focused research collaborations with major pharma partners, and is deploying GEMS to advance an internal therapeutics pipeline for a variety of high-impact targets. Investors include Rock Springs Capital, T. Rowe Price, Menlo Ventures, Radical Ventures, Andreessen Horowitz, Nventures (NVIDIA’s venture capital arm), and others.